Claims for Patent: 10,006,091

Summary for Patent: 10,006,091

Title:	Method for the diagnosis, prognosis and treatment of lung cancer metastasis
Abstract:	The present invention relates to a method for the diagnosis or the prognosis of metastasis in lung cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in lung cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the lung cancer.
Inventor(s):	Gomis; Roger (Barcelona, ES), Planet; Evarist (Barcelona, ES)
Assignee:	Fundacio Institut de Recerca Biomedica (IRB Barcelona) (Barcelona, ES) Institucio Catalana de Recerca I Estudis Avancats (Barcelona, ES)
Application Number:	14/405,724
Patent Claims:	1. A method for treating and/or preventing bone metastasis in a subject suffering lung cancer with elevated c-MAF levels in a metastatic tumor sample with respect to a control sample, comprising administering a therapeutically effective amount of an agent capable of treating, reducing and/or preventing bone degradation to the subject suffering lung cancer, wherein the agent capable of treating, reducing and/or preventing bone degradation is selected from the group consisting of zoledronic acid and denosumab. 2. The method according to claim 1, wherein the agent capable of treating, reducing and/or preventing bone degradation is denosumab. 3. The method according to claim 1, wherein the agent capable of treating, reducing and/or preventing bone degradation is zoledronic acid. 4. The method according to claim 1, wherein the lung cancer is small-cell lung cancer (SCLC) or non-small-cell lung cancer (NSCLC). 5. The method according to claim 1, wherein the bone metastasis is osteolytic metastasis. 6. The method according to claim 1, wherein the lung cancer is lung adenocarcinoma. 7. A method for treating and/or preventing bone metastasis in a subject suffering lung cancer, said method comprising administering to said subject an agent capable of treating, reducing and/or preventing bone degradation, wherein said agent is administered in accordance with a treatment regimen determined from quantifying the expression level, gene copy number or amplification of c-MAF in said subject, wherein the agent capable of treating, reducing and/or preventing bone degradation is selected from the group consisting of zoledronic acid and denosumab. 8. A method for treating a subject suffering lung cancer which comprises i) quantifying the c-MAF gene expression level, gene copy number or amplification in a sample of said subject and ii) comparing the value obtained in i) with a reference value, wherein if the value is increased with respect to said reference value, then said subject is administered a therapeutically effective amount of an agent capable of treating, reducing and/or preventing bone degradation, wherein the agent capable of treating, reducing and/or preventing bone degradation is selected from the group consisting of zoledronic acid and denosumab. 9. The method according to claim 7, wherein the agent capable of treating, reducing and/or preventing bone degradation is denosumab. 10. The method according to claim 7, wherein the agent capable of treating, reducing and/or preventing bone degradation is zoledronic acid. 11. The method according to claim 7, wherein the lung cancer is SCLC or NSCLC or lung adenocarcinoma. 12. The method according to claim 7, wherein the bone metastasis is osteolytic metastasis. 13. The method according to claim 8, wherein the agent capable of treating, reducing and/or preventing bone degradation is denosumab. 14. The method according to claim 8, wherein the agent capable of treating, reducing and/or preventing bone degradation is zoledronic acid. 15. The method according to claim 8, wherein the lung cancer is SCLC or NSCLC or lung adenocarcinoma. 16. The method according to claim 1, wherein the method is a method for treating bone metastasis. 17. The method according to claim 7, wherein the method is a method for treating bone metastasis. 18. The method of any one of claims 1, 7 or 8, wherein the agent capable of treating, reducing and/or preventing bone degradation is an agent capable of treating and/or reducing bone degradation. 19. The method according to claim 1, wherein the lung cancer is SCLC. 20. The method according to claim 1, wherein the lung cancer is NSCLC. 21. The method according to claim 1, wherein the subject is a human. 22. The method according to claim 7, wherein the lung cancer is SCLC. 23. The method according to claim 7, wherein the lung cancer is NSCLC. 24. The method according to claim 7, wherein the lung cancer is lung adenocarcinoma. 25. The method according to claim 7, wherein the subject is a human. 26. The method according to claim 8, wherein the lung cancer is SCLC. 27. The method according to claim 8, wherein the lung cancer is NSCLC. 28. The method according to claim 8, wherein the lung cancer is lung adenocarcinoma. 29. The method according to claim 8, wherein the subject is a human.

Details for Patent 10,006,091

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	PROLIA	denosumab	Injection	125320	June 01, 2010	10,006,091	2039-02-26
Amgen Inc.	XGEVA	denosumab	Injection	125320	November 18, 2010	10,006,091	2039-02-26